Boundless Bio $100M IPO Sparks Excitement in Oncology Drug Development
Friday, 8 March 2024, 22:31
Boundless Bio Announces $100M IPO
Boundless Bio (BOLD), a developer of ecDNA-directed oncology therapeutics, has filed for a proposed $100M initial public offering.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.